Intra-Cellular Therapies (ITCI) has released an update.
The recent press release from the Company on February 22, 2024, offers a comprehensive update on its business progress, with specific details on commercial achievements, clinical developments, and information on CAPLYTA (lumateperone) and Intra-Cellular Therapies. Additionally, the forward-looking statements in the release carry a disclaimer, all of which are now included in the Current Report, enhancing transparency for stakeholders and those monitoring the financial markets.
For further insights into ITCI stock, check out TipRanks’ Stock Analysis page.
